Purpose We sought to indirectly compare and rank antiarrhythmic agents focusing
exclusively on adults with paroxysmal atrial fibrillation in order to identify the most effective …

Background Atrial fibrillation (AF) accounts for approximately one-third of hospitalizations for
cardiac rhythm disturbances. Little is known about the characteristics of current use of …

—Hippocrates (1) The need of proper anticoagulation for cardioversion of atrial fibrillation
(AF) episodes with duration $48 h is well established. Nonanticoagulated patients carry a …

Pharmacological cardioversion using intravenous antiarrhythmic agents is commonly
indicated in symptomatic patients with recent‐onset atrial fibrillation (AF). Except in …

Restoring sinus rhythm either with pharmacological or electrical therapies is a desirable end-
point, at least in certain subsets of patients with atrial fibrillation. It may be achieved in 70 …

Currently, there is no unified consensus on short-term anticoagulation after cardioversion of
atrial fibrillation lasting less than 48 h in low-cardioembolic-risk patients. The aim of this …

Aims Single oral dose anti-arrhythmic drugs (AADs) are used to cardiovert recent-onset
atrial fibrillation (AF); however, the optimal agent is uncertain. Methods We performed a …

Focuses on the issues to be considered in deciding whether and when to apply
cardioversion in chronic atrial fibrillation (AF). Range of pharmacological and electrical …

Background: Atrial fibrillation is the most common sustained cardiac arrhythmia and has an
important impact on costs of medical assistance. Traditional interventions to convert atrial …

Atrial fibrillation (AF) is the most frequent chronic arrhythmia worldwide, and it is associated
with significant morbidity and mortality, making it a considerable burden both to patients and …